Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Increases By 19.6%

Lyell Immunopharma, Inc. (NASDAQ:LYEL) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 24,150,000 shares, an increase of 19.6% from the May 31st total of 20,200,000 shares. Based on an average trading volume of 788,600 shares, the short-interest ratio is presently 30.6 days. Approximately 20.4% of the shares of the stock are short sold.

Lyell Immunopharma Stock Down 4.4 %

Shares of Lyell Immunopharma stock traded down $0.07 during mid-day trading on Tuesday, hitting $1.51. The stock had a trading volume of 934,752 shares, compared to its average volume of 1,033,032. The firm has a 50-day moving average of $2.38 and a two-hundred day moving average of $2.24. Lyell Immunopharma has a 12-month low of $1.18 and a 12-month high of $3.41. The firm has a market cap of $384.96 million, a P/E ratio of -1.68 and a beta of -0.52.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Lyell Immunopharma had a negative net margin of 335,794.09% and a negative return on equity of 33.92%. Sell-side analysts expect that Lyell Immunopharma will post -0.85 earnings per share for the current year.

Institutional Trading of Lyell Immunopharma

Several hedge funds have recently made changes to their positions in the company. WuXi AppTec Co. Ltd. purchased a new position in shares of Lyell Immunopharma during the 4th quarter worth approximately $15,871,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Lyell Immunopharma by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,137 shares of the company’s stock worth $57,000 after purchasing an additional 22,701 shares during the period. Invenomic Capital Management LP purchased a new position in shares of Lyell Immunopharma during the 4th quarter worth approximately $1,448,000. Public Employees Retirement System of Ohio boosted its position in shares of Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock worth $40,000 after purchasing an additional 14,229 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of Lyell Immunopharma by 81.9% during the 4th quarter. SG Americas Securities LLC now owns 99,221 shares of the company’s stock worth $192,000 after purchasing an additional 44,686 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on LYEL. Bank of America dropped their price objective on shares of Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, June 27th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Lyell Immunopharma in a research note on Thursday, June 27th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.